Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

End of Quarter Sale - 50% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Novo Nordisk ( (NVO) ) has provided an announcement.

Novo Nordisk, a leading Danish healthcare group specialising in treatments for serious chronic diseases, including diabetes, employs about 68,800 people and sells its products in roughly 170 countries. Its B shares trade on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange, anchoring the company firmly in both European and U.S. capital markets.

On 30 March 2026, Novo Nordisk reported progress on the share repurchase programme it launched on 4 February 2026, which is part of a broader plan to buy back up to DKK 15 billion of B shares over 12 months. Between 23 and 27 March 2026, the company repurchased 1,315,000 B shares, bringing total buybacks since early February to 9,162,992 B shares worth about DKK 2.4 billion, and lifting treasury holdings to 26,552,791 B shares, or roughly 0.6% of its share capital, underscoring an ongoing commitment to shareholder returns.

The most recent analyst rating on (NVO) stock is a Hold with a $39.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.

Spark’s Take on NVO Stock

According to Spark, TipRanks’ AI Analyst, NVO is a Neutral.

The score reflects strong underlying financial quality and attractive valuation, partially offset by a very weak technical setup (downtrend across all key moving averages) and a cautious near-term outlook from management, including guidance for declining 2026 sales and operating profit amid pricing and policy headwinds.

To see Spark’s full report on NVO stock, click here.

More about Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, focused on defeating serious chronic diseases with a heritage in diabetes care. The company pioneers scientific breakthroughs, expands access to its medicines, and works to prevent and ultimately cure disease, employing about 68,800 people in 80 countries and marketing its products in around 170 countries.

Average Trading Volume: 24,151,425

Technical Sentiment Signal: Sell

Current Market Cap: $156.3B

See more data about NVO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue